These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18368614)

  • 1. Technology and innovation in the psychosocial treatment of methamphetamine use, risk and dependence.
    Kay-Lambkin FJ
    Drug Alcohol Rev; 2008 May; 27(3):318-25. PubMed ID: 18368614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methamphetamine and cardiovascular pathology: a review of the evidence.
    Kaye S; McKetin R; Duflou J; Darke S
    Addiction; 2007 Aug; 102(8):1204-11. PubMed ID: 17565561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Socio-demographic factors associated with methamphetamine treatment contact among dependent methamphetamine users in Sydney, Australia.
    McKetin R; Kelly E
    Drug Alcohol Rev; 2007 Mar; 26(2):161-8. PubMed ID: 17364851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidemiology of methamphetamine use and harm in Australia.
    Degenhardt L; Roxburgh A; Black E; Bruno R; Campbell G; Kinner S; Fetherston J
    Drug Alcohol Rev; 2008 May; 27(3):243-52. PubMed ID: 18368605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quite a lot of smoke but very limited fire--the use of methamphetamine in Europe.
    Griffiths P; Mravcik V; Lopez D; Klempova D
    Drug Alcohol Rev; 2008 May; 27(3):236-42. PubMed ID: 18368604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical course and outcomes of methamphetamine-dependent adults with psychosis.
    Glasner-Edwards S; Mooney LJ; Marinelli-Casey P; Hillhouse M; Ang A; Rawson R;
    J Subst Abuse Treat; 2008 Dec; 35(4):445-50. PubMed ID: 18294802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contingency management: an evidence-based component of methamphetamine use disorder treatments.
    Roll JM
    Addiction; 2007 Apr; 102 Suppl 1():114-20. PubMed ID: 17493060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug court treatment for methamphetamine dependence: treatment response and posttreatment outcomes.
    Marinelli-Casey P; Gonzales R; Hillhouse M; Ang A; Zweben J; Cohen J; Hora PF; Rawson RA;
    J Subst Abuse Treat; 2008 Mar; 34(2):242-8. PubMed ID: 17596903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Major physical and psychological harms of methamphetamine use.
    Darke S; Kaye S; McKetin R; Duflou J
    Drug Alcohol Rev; 2008 May; 27(3):253-62. PubMed ID: 18368606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methamphetamine: geographic areas and populations at risk, and emerging evidence for effective interventions.
    Degenhardt L; Baker A; Maher L
    Drug Alcohol Rev; 2008 May; 27(3):217-9. PubMed ID: 18368601
    [No Abstract]   [Full Text] [Related]  

  • 11. Crystal methamphetamine smoking among regular ecstasy users in Australia: increases in use and associations with harm.
    Kinner SA; Degenhardt L
    Drug Alcohol Rev; 2008 May; 27(3):292-300. PubMed ID: 18368611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and harms associated with injecting versus smoking methamphetamine among methamphetamine treatment entrants.
    McKetin R; Ross J; Kelly E; Baker A; Lee N; Lubman DI; Mattick R
    Drug Alcohol Rev; 2008 May; 27(3):277-85. PubMed ID: 18368609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating treatments for methamphetamine abuse: a psychosocial perspective.
    Huber A; Ling W; Shoptaw S; Gulati V; Brethen P; Rawson R
    J Addict Dis; 1997; 16(4):41-50. PubMed ID: 9328808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methamphetamine use, dependence and treatment access in rural and regional North Coast of New South Wales, Australia.
    Wallace C; Galloway T; McKetin R; Kelly E; Leary J
    Drug Alcohol Rev; 2009 Nov; 28(6):592-9. PubMed ID: 19930011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
    Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
    Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions.
    Rose ME; Grant JE
    Ann Clin Psychiatry; 2008; 20(3):145-55. PubMed ID: 18633741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why do we need an Addiction supplement focused on methamphetamine?
    Rawson RA; Condon TP
    Addiction; 2007 Apr; 102 Suppl 1():1-4. PubMed ID: 17493048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to methamphetamine withdrawal treatment in Australia: findings from a survey of AOD service providers.
    Pennay AE; Lee NK
    Drug Alcohol Rev; 2009 Nov; 28(6):636-40. PubMed ID: 19930017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methamphetamine and its impact on dental care.
    Klasser GD; Epstein J
    J Can Dent Assoc; 2005 Nov; 71(10):759-62. PubMed ID: 16324229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users.
    Kim DJ; Roh S; Kim Y; Yoon SJ; Lee HK; Han CS; Kim YK
    Neurosci Lett; 2005 Nov; 388(2):112-5. PubMed ID: 16039058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.